Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2002 Jun;72(6):708–712. doi: 10.1136/jnnp.72.6.708

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

D Aarsland 1, K Laake 1, J Larsen 1, C Janvin 1
PMCID: PMC1737925  PMID: 12023410

Abstract

Objective: To study the safety and efficacy of the cholinesterase inhibitor donepezil in patients with Parkinson's disease (PD) and cognitive impairment.

Methods: This was a double blind, randomised and placebo controlled, crossover study in which 14 patients with PD and cognitive impairment received donepezil (5 or 10 mg per day) or matching placebo during two sequential periods lasting 10 weeks each. The primary outcome measures were the mini mental state examination (MMSE) score, the clinician's interview based impression of change plus caregiver input (CIBIC+) score, and the motor subscale of the unified Parkinson's disease rating scale (UPDRS).

Results: Two patients on donepezil (14%) dropped out after one and four weeks of the first treatment period because of peripheral cholinergic side effects, otherwise the adverse effects were few and not severe. Carryover or residual effects were not observed. Parkinsonism did not increase during donepezil treatment. After 10 weeks of treatment, the mean MMSE score was increased by 2.1(SD 2.7) points on donepezil and 0.3 (SD 3.2) points on placebo, and the CIBIC+ score was 3.3 (SD 0.9) on donepezil and 4.1 (SD 0.8) on placebo. Statistical analysis of the repeated measurements and crossover study design showed significant effects of donepezil compared with placebo for MMSE (p=0.013) and CIBIC+ (p=0.034). Five (42%) patients on donepezil and two (17%) on placebo were rated as improved on the basis of the CIBIC+ score.

Conclusions: Donepezil improves cognition, and seems to be well tolerated and not to worsen parkinsonism in patients with cognitive impairment.

Full Text

The Full Text of this article is available as a PDF (102.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarsland D., Andersen K., Larsen J. P., Lolk A., Nielsen H., Kragh-Sørensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology. 2001 Mar 27;56(6):730–736. doi: 10.1212/wnl.56.6.730. [DOI] [PubMed] [Google Scholar]
  2. Aarsland D., Larsen J. P., Karlsen K., Lim N. G., Tandberg E. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry. 1999 Oct;14(10):866–874. [PubMed] [Google Scholar]
  3. Aarsland D., Larsen J. P., Tandberg E., Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc. 2000 Aug;48(8):938–942. doi: 10.1111/j.1532-5415.2000.tb06891.x. [DOI] [PubMed] [Google Scholar]
  4. Aarsland D., Tandberg E., Larsen J. P., Cummings J. L. Frequency of dementia in Parkinson disease. Arch Neurol. 1996 Jun;53(6):538–542. doi: 10.1001/archneur.1996.00550060082020. [DOI] [PubMed] [Google Scholar]
  5. Cummings J. L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D. A., Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994 Dec;44(12):2308–2314. doi: 10.1212/wnl.44.12.2308. [DOI] [PubMed] [Google Scholar]
  6. Folstein M. F., Folstein S. E., McHugh P. R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6. [DOI] [PubMed] [Google Scholar]
  7. Forno L. S. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol. 1996 Mar;55(3):259–272. doi: 10.1097/00005072-199603000-00001. [DOI] [PubMed] [Google Scholar]
  8. Gelb D. J., Oliver E., Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999 Jan;56(1):33–39. doi: 10.1001/archneur.56.1.33. [DOI] [PubMed] [Google Scholar]
  9. Greenberg S. M., Tennis M. K., Brown L. B., Gomez-Isla T., Hayden D. L., Schoenfeld D. A., Walsh K. L., Corwin C., Daffner K. R., Friedman P. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol. 2000 Jan;57(1):94–99. doi: 10.1001/archneur.57.1.94. [DOI] [PubMed] [Google Scholar]
  10. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  11. Hughes A. J., Daniel S. E., Blankson S., Lees A. J. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol. 1993 Feb;50(2):140–148. doi: 10.1001/archneur.1993.00540020018011. [DOI] [PubMed] [Google Scholar]
  12. Hurtig H. I., Trojanowski J. Q., Galvin J., Ewbank D., Schmidt M. L., Lee V. M., Clark C. M., Glosser G., Stern M. B., Gollomp S. M. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology. 2000 May 23;54(10):1916–1921. doi: 10.1212/wnl.54.10.1916. [DOI] [PubMed] [Google Scholar]
  13. Hutchinson M., Fazzini E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):324–325. doi: 10.1136/jnnp.61.3.324-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kuhl D. E., Minoshima S., Fessler J. A., Frey K. A., Foster N. L., Ficaro E. P., Wieland D. M., Koeppe R. A. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol. 1996 Sep;40(3):399–410. doi: 10.1002/ana.410400309. [DOI] [PubMed] [Google Scholar]
  15. Larsen J. P., Dupont E., Tandberg E. Clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand. 1994 Apr;89(4):242–251. doi: 10.1111/j.1600-0404.1994.tb01674.x. [DOI] [PubMed] [Google Scholar]
  16. Litvan I., MacIntyre A., Goetz C. G., Wenning G. K., Jellinger K., Verny M., Bartko J. J., Jankovic J., McKee A., Brandel J. P. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998 Jul;55(7):969–978. doi: 10.1001/archneur.55.7.969. [DOI] [PubMed] [Google Scholar]
  17. McKeith I. G., Galasko D., Kosaka K., Perry E. K., Dickson D. W., Hansen L. A., Salmon D. P., Lowe J., Mirra S. S., Byrne E. J. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996 Nov;47(5):1113–1124. doi: 10.1212/wnl.47.5.1113. [DOI] [PubMed] [Google Scholar]
  18. McKeith I. G. Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. Neurol Clin. 2000 Nov;18(4):865–902. doi: 10.1016/s0733-8619(05)70230-9. [DOI] [PubMed] [Google Scholar]
  19. McKeith I., Del Ser T., Spano P., Emre M., Wesnes K., Anand R., Cicin-Sain A., Ferrara R., Spiegel R. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000 Dec 16;356(9247):2031–2036. doi: 10.1016/S0140-6736(00)03399-7. [DOI] [PubMed] [Google Scholar]
  20. Perry E. K., Curtis M., Dick D. J., Candy J. M., Atack J. R., Bloxham C. A., Blessed G., Fairbairn A., Tomlinson B. E., Perry R. H. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1985 May;48(5):413–421. doi: 10.1136/jnnp.48.5.413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Perry E. K., Irving D., Kerwin J. M., McKeith I. G., Thompson P., Collerton D., Fairbairn A. F., Ince P. G., Morris C. M., Cheng A. V. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord. 1993 Summer;7(2):69–79. doi: 10.1097/00002093-199307020-00002. [DOI] [PubMed] [Google Scholar]
  22. Rogers S. L., Farlow M. R., Doody R. S., Mohs R., Friedhoff L. T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998 Jan;50(1):136–145. doi: 10.1212/wnl.50.1.136. [DOI] [PubMed] [Google Scholar]
  23. Samuel W., Caligiuri M., Galasko D., Lacro J., Marini M., McClure F. S., Warren K., Jeste D. V. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry. 2000 Sep;15(9):794–802. doi: 10.1002/1099-1166(200009)15:9<794::aid-gps178>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  24. Tandberg E., Larsen J. P., Nessler E. G., Riise T., Aarli J. A. The epidemiology of Parkinson's disease in the county of Rogaland, Norway. Mov Disord. 1995 Sep;10(5):541–549. doi: 10.1002/mds.870100503. [DOI] [PubMed] [Google Scholar]
  25. Tiraboschi P., Hansen L. A., Alford M., Sabbagh M. N., Schoos B., Masliah E., Thal L. J., Corey-Bloom J. Cholinergic dysfunction in diseases with Lewy bodies. Neurology. 2000 Jan 25;54(2):407–411. doi: 10.1212/wnl.54.2.407. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

[Correction]
jnnpsyc_72_6_708__index.html (872B, html)

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES